These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31758842)

  • 1. Decitabine limits escape from MEK inhibition in uveal melanoma.
    Gonçalves J; Emmons MF; Faião-Flores F; Aplin AE; Harbour JW; Licht JD; Wink MR; Smalley KSM
    Pigment Cell Melanoma Res; 2020 May; 33(3):507-514. PubMed ID: 31758842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
    Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
    Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
    Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
    Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC Inhibition Enhances the
    Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
    Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
    Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
    Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
    Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
    Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
    Sriramareddy SN; Faião-Flores F; Emmons MF; Saha B; Chellappan S; Wyatt C; Smalley I; Licht JD; Durante MA; Harbour JW; Smalley KSM
    Cancer Gene Ther; 2022 Dec; 29(12):1840-1846. PubMed ID: 35332245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X; Zhu A; Gu X; Xie G
    Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.
    Takemoto M; Tanaka T; Tsuji R; Togashi Y; Higashi M; Fumino S; Tajiri T
    Biochem Biophys Res Commun; 2021 Sep; 570():41-46. PubMed ID: 34271435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Wang Y; Liu M; Jin Y; Jiang S; Pan J
    Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
    Mergener S; Siveke JT; Peña-Llopis S
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
    Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.